Phase 1 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have been diagnosed with Acute Myeloid Leukaemia (AML) according to 2016 World Health Organization standards and have not yet received any treatment for it
- People whose AML has tested positive for a protein called CD123, confirmed through laboratory testing at diagnosis or at the time of screening
- People whose doctors have determined they are not suitable for standard intensive chemotherapy ("induction therapy"), based on at least one of the following: being 75 years of age or older; having limited physical functioning (ECOG score of 2 or 3); having a heart condition such as heart failure, reduced heart pumping function, or stable chest pain; having a lung condition with reduced lung function; having moderately reduced kidney function within a specific range; or having a liver condition causing mildly to moderately elevated bilirubin levels within a specific range (confirm with trial site)
- People with an expected life expectancy of at least 12 weeks
Who may not be able to join:
- People who have previously received certain blood cancer treatments, including hypomethylating agents, venetoclax, or chemotherapy for AML, MDS, CMML, or related blood disorders
- People who have previously received CAR-T cell therapy or a stem cell transplant from a donor
- People who have previously received experimental treatments for AML or MDS
- People who are currently taking part in another clinical research study that involves a treatment intervention
- People with a history of certain other blood or bone marrow conditions, including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukaemia, or AML with a specific genetic feature called BCR-ABL1
- People who have a type of leukaemia called acute promyelocytic leukaemia (APL)
- People with an active autoimmune condition that requires high-dose steroid or immunosuppressive treatment above a certain threshold
- People currently receiving corticosteroids as part of cancer treatment at any dose
- People with known active spread of AML to the brain or spinal fluid (note: people who received preventive treatment to the spinal fluid before joining may still be considered eligible — confirm with trial site)
- People with severely reduced kidney function below a specific threshold (confirm with trial site)
- People with significantly elevated bilirubin liver levels above three times the normal upper limit, unless they have a condition called Gilbert's Syndrome
- People with significantly elevated liver enzyme levels (AST and/or ALT) more than three times the normal upper limit
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Dirk Huebner, MD, Aptevo Therapeutics
Phone: 7735749572
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess the safety, tolerability, and maximum tolerated dose (MTD) of increasing doses of APVO436 in combination with venetoclax/azacitidine in patients with newly diagnosed AML
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.